News & Updates

Baricitinib compares favourably with filgotinib for RA

25 May 2025

In the treatment of patients with rheumatoid arthritis, baricitinib is equally effective as filgotinib at reducing disease activity, with similar drug retention rates, according to a retrospective study.

Baricitinib compares favourably with filgotinib for RA

25 May 2025

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025 by

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025 by

A multinational phase I study led by the Chinese University of Hong Kong (CUHK) reports an overall objective response rate (ORR) of >70 percent in advanced solid KRAS^G12C-mutant tumours treated with D3S-001, a next-generation KRAS^G12C inhibitor developed in mainland China.

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025

VMR tied to severe COPD exacerbation

25 May 2025

Visceral fat-to-muscle ratio (VMR) can be used to predict the severe exacerbation of chronic obstructive pulmonary disease (COPD), suggests a study.

VMR tied to severe COPD exacerbation

25 May 2025

Neonatal vitamin D status linked to mental disorder risks

25 May 2025

Individuals with vitamin D deficiency as neonates face a heightened risk of mental disorders, according to a study.

Neonatal vitamin D status linked to mental disorder risks

25 May 2025

HF hospitalization risk greater in IMID patients

24 May 2025

Patients with immune-mediated inflammatory disease (IMID) are at increased risk of hospitalization for heart failure (HF) when compared to the general population, reveals a study.

HF hospitalization risk greater in IMID patients

24 May 2025

Low HDL-C levels may heighten risk of acromegaly

24 May 2025

Individuals with low high-density lipoprotein cholesterol (HDL-C) levels face an increased risk of acromegaly, according to a large retrospective study from Korea.

Low HDL-C levels may heighten risk of acromegaly

24 May 2025

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

24 May 2025 by

Cardiac myosin inhibitors (CMIs) for obstructive hypertrophic cardiomyopathy (HCM) offer effective treatment targeting the underlying pathophysiology of the disease and are recommended as a second-line (2L) option in latest international guidelines. At the 10^th Asian Preventive Cardiology & Cardiac Rehabilitation Conference, Dr Raymond H Chan of the Hypertrophic Cardiomyopathy Clinic, University Health Network, Peter Munk Cardiac Center in Toronto, Canada, discussed why CMIs are game-changers in HCM management and presented a patient case illustrating real-world benefits of the first-in-class CMI, mavacamten.

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

24 May 2025

$Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA$

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

24 May 2025 by

A 57-year-old lady presented in January 2015 with bilateral lower limb numbness, vasculitic rash over her lower limb, shortness of breath, and sudden loss of vision in her left eye. She had a history of adult-onset asthma for more than 10 years (managed with inhaled corticosteroids and bronchodilator), and had two episodes of exacerbation 6 months before presentation. Other comorbidities included allergic rhinitis and paroxysmal atrial fibrillation.

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

24 May 2025

Plant-based fasting-mimicking diet does not boost medication response in UC

23 May 2025

The low-calorie, plant-based fasting-mimicking (LC-PB) diet does little to improve clinical response to medications in patients with active ulcerative colitis (UC), according to a study. However, LC-PB diet helps with steroid tapering and reduce serum amyloid A.

Plant-based fasting-mimicking diet does not boost medication response in UC

23 May 2025

News & Updates

Filter by Specialty:

Specialty:

Baricitinib compares favourably with filgotinib for RA

Baricitinib compares favourably with filgotinib for RA

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

VMR tied to severe COPD exacerbation

VMR tied to severe COPD exacerbation

Neonatal vitamin D status linked to mental disorder risks

Neonatal vitamin D status linked to mental disorder risks

HF hospitalization risk greater in IMID patients

HF hospitalization risk greater in IMID patients

Low HDL-C levels may heighten risk of acromegaly

Low HDL-C levels may heighten risk of acromegaly

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

Plant-based fasting-mimicking diet does not boost medication response in UC

Plant-based fasting-mimicking diet does not boost medication response in UC